Biora Therapeutics (BIOR) Competitors $0.13 0.00 (0.00%) As of 02/19/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BIOR vs. PCSA, PTIX, KTTA, SLXN, APVO, CDT, ERNA, PBLA, GLMD, and VRPXShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Processa Pharmaceuticals (PCSA), Protagenic Therapeutics (PTIX), Pasithea Therapeutics (KTTA), Silexion Therapeutics (SLXN), Aptevo Therapeutics (APVO), Conduit Pharmaceuticals (CDT), Eterna Therapeutics (ERNA), Panbela Therapeutics (PBLA), Galmed Pharmaceuticals (GLMD), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Processa Pharmaceuticals Protagenic Therapeutics Pasithea Therapeutics Silexion Therapeutics Aptevo Therapeutics Conduit Pharmaceuticals Eterna Therapeutics Panbela Therapeutics Galmed Pharmaceuticals Virpax Pharmaceuticals Processa Pharmaceuticals (NASDAQ:PCSA) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking. Which has preferable valuation & earnings, PCSA or BIOR? Processa Pharmaceuticals has higher earnings, but lower revenue than Biora Therapeutics. Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcessa PharmaceuticalsN/AN/A-$11.12M-$3.39-0.16Biora Therapeutics$892K0.66-$124.11M-$13.04-0.01 Do analysts rate PCSA or BIOR? Processa Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 1,032.08%. Biora Therapeutics has a consensus price target of $23.00, indicating a potential upside of 17,592.31%. Given Biora Therapeutics' higher possible upside, analysts plainly believe Biora Therapeutics is more favorable than Processa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PCSA or BIOR more profitable? Biora Therapeutics' return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Processa PharmaceuticalsN/A -195.21% -163.06% Biora Therapeutics N/A N/A -332.47% Does the MarketBeat Community prefer PCSA or BIOR? Processa Pharmaceuticals received 7 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Biora Therapeutics an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Biora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% Do institutionals & insiders have more ownership in PCSA or BIOR? 91.9% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 13.0% of Processa Pharmaceuticals shares are held by company insiders. Comparatively, 51.1% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to PCSA or BIOR? In the previous week, Processa Pharmaceuticals had 1 more articles in the media than Biora Therapeutics. MarketBeat recorded 1 mentions for Processa Pharmaceuticals and 0 mentions for Biora Therapeutics. Processa Pharmaceuticals' average media sentiment score of 1.32 beat Biora Therapeutics' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Processa Pharmaceuticals Positive Biora Therapeutics Neutral Which has more risk & volatility, PCSA or BIOR? Processa Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. SummaryProcessa Pharmaceuticals beats Biora Therapeutics on 8 of the 15 factors compared between the two stocks. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$588,000.00$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.016.1326.4618.82Price / Sales0.66312.32457.0180.82Price / CashN/A67.8344.0437.47Price / Book0.006.747.634.64Net Income-$124.11M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.02%-1.82%-2.63%1 Month Performance-20.25%-1.54%0.22%-2.37%1 Year Performance-98.45%-3.14%17.49%13.65% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics1.8319 of 5 stars$0.13flat$23.00+17,592.3%-98.5%$588,000.00$892,000.00-0.01120PCSAProcessa Pharmaceuticals3.5951 of 5 stars$0.60-1.7%$6.00+898.3%-77.8%$1.97MN/A-0.1820PTIXProtagenic TherapeuticsN/A$0.27-2.5%N/A-74.0%$1.94MN/A-0.212KTTAPasithea Therapeutics0.7731 of 5 stars$1.45-0.7%N/A-82.6%$1.84MN/A0.003SLXNSilexion TherapeuticsN/A$1.08-15.0%$9.00+733.3%N/A$1.73MN/A0.00N/AAPVOAptevo Therapeutics2.3905 of 5 stars$3.34-8.2%$10,952.00+327,804.2%-100.0%$1.70M$3.11M0.0050Analyst RevisionNews CoverageHigh Trading VolumeCDTConduit PharmaceuticalsN/A$1.64+0.6%N/A-99.6%$1.69MN/A0.003ERNAEterna TherapeuticsN/A$0.31+6.7%N/A-78.0%$1.66M$70,000.00-0.0410Positive NewsGap UpPBLAPanbela TherapeuticsN/A$0.34+6.3%N/A-72.9%$1.65MN/A0.006GLMDGalmed Pharmaceuticals0.7007 of 5 stars$2.56+1.6%N/A-44.0%$1.64MN/A-0.1520VRPXVirpax Pharmaceuticals1.4496 of 5 stars$0.33+12.9%$3.00+819.4%-89.3%$1.60MN/A0.007Gap UpHigh Trading Volume Related Companies and Tools Related Companies Processa Pharmaceuticals Competitors Protagenic Therapeutics Competitors Pasithea Therapeutics Competitors Silexion Therapeutics Competitors Aptevo Therapeutics Competitors Conduit Pharmaceuticals Competitors Eterna Therapeutics Competitors Panbela Therapeutics Competitors Galmed Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIOR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
